Credit Suisse Group reiterated their outperform rating on shares of GALAPAGOS NV/S (NASDAQ:GLPG) in a report released on Wednesday morning, Briefing.com Automated Import reports.
A number of other research analysts have also recently commented on GLPG. ValuEngine upgraded shares of XPO Logistics from a strong sell rating to a sell rating in a report on Thursday, April 4th. Cantor Fitzgerald restated a buy rating and issued a $25.00 price target on shares of Menlo Therapeutics in a report on Thursday, May 2nd. HC Wainwright set a $10.00 price target on shares of Jaguar Health and gave the stock a buy rating in a report on Tuesday, July 2nd. Morgan Stanley upped their price target on shares of Thomson Reuters from $66.00 to $67.00 and gave the stock an overweight rating in a report on Monday, April 29th. Finally, BidaskClub cut shares of Amyris from a hold rating to a sell rating in a report on Thursday, June 27th. One research analyst has rated the stock with a hold rating, eleven have given a buy rating and three have assigned a strong buy rating to the company. GALAPAGOS NV/S presently has a consensus rating of Buy and a consensus price target of $134.90.
GLPG stock opened at $145.75 on Wednesday. The company has a current ratio of 6.31, a quick ratio of 6.31 and a debt-to-equity ratio of 0.02. GALAPAGOS NV/S has a twelve month low of $85.00 and a twelve month high of $146.13. The company’s fifty day moving average price is $125.33.
GALAPAGOS NV/S (NASDAQ:GLPG) last posted its quarterly earnings data on Friday, April 26th. The biotechnology company reported ($1.01) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($1.19) by $0.18. GALAPAGOS NV/S had a negative net margin of 13.24% and a negative return on equity of 3.60%. The business had revenue of $46.47 million for the quarter, compared to analysts’ expectations of $44.92 million. As a group, analysts anticipate that GALAPAGOS NV/S will post -4.61 EPS for the current fiscal year.
A number of institutional investors have recently modified their holdings of the business. Pinnacle Associates Ltd. purchased a new stake in shares of GALAPAGOS NV/S during the first quarter valued at about $231,000. Financial Gravity Wealth Inc. purchased a new stake in shares of GALAPAGOS NV/S during the first quarter valued at about $344,000. Comerica Bank lifted its position in shares of GALAPAGOS NV/S by 6.3% during the fourth quarter. Comerica Bank now owns 3,120 shares of the biotechnology company’s stock valued at $325,000 after buying an additional 185 shares during the last quarter. Stevens Capital Management LP purchased a new stake in shares of GALAPAGOS NV/S during the first quarter valued at about $398,000. Finally, DekaBank Deutsche Girozentrale lifted its position in shares of GALAPAGOS NV/S by 121.4% during the first quarter. DekaBank Deutsche Girozentrale now owns 6,200 shares of the biotechnology company’s stock valued at $632,000 after buying an additional 3,400 shares during the last quarter. Institutional investors own 16.33% of the company’s stock.
About GALAPAGOS NV/S
Galapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes novel medicines. Its clinical stage programs include filgotinib, which is in Phase III clinical trials for the treatment of rheumatoid arthritis and Crohn's disease, Phase 2/3 trials for ulcerative colitis, and Phase II trials for multiple additional indications; GLPG1690, an autotaxin inhibitor, which is in Phase III clinical trial for the treatment of idiopathic pulmonary fibrosis; GLPG1972 that completed Phase 1b clinical trial for the treatment of osteoarthritis; and MOR106, which is in Phase II trials for atopic dermatitis patients.
Featured Article: Why are trading ranges significant?
Receive News & Ratings for GALAPAGOS NV/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GALAPAGOS NV/S and related companies with MarketBeat.com's FREE daily email newsletter.